AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in Japan for the treatment of adult patients with unresectable or recurrent PIK3CA, AKT1, or PTEN-altered hormone receptor (HR)-positive, HER2-negative breast cancer following progression after treatment with endocrine therapy.
The National Institute of Health and Care Excellence (NICE) released draft guidance recommending against use of Faslodex (fulvestrant) from AstraZeneca...
The latest findings presented today at the 2014 San Antonio Breast Cancer Symposium (SABCS) show that investigational first-line treatment with fulvestrant...
Eli Lilly announced that results from the Phase III MONARCH 2 study showed that LY 2835219 (abemaciclib) in combination with...
This phase III study evaluated ribociclib plus fulvestrant in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer who were treatment naïve or had received up to one line of prior endocrine therapy in the advanced setting.
Novartis has announced additional analysis from the global Phase III SOLAR-1 trial investigating the alpha-specific PI3K inhibitor BYL 719 (alpelisib)...
New data from the Phase III FALCON trial demonstrates superior median progression-free survival (PFS) for Faslodex (fulvestrant 500mg), from AstraZeneca,...